BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» BMS identifies selective inhibitors and heterobifunctional degraders of CAMKK2
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ACS Fall 2022
BMS identifies selective inhibitors and heterobifunctional degraders of CAMKK2
Aug. 31, 2022
No Comments
Identification of selective, ligand-efficient ATP-competitive inhibitors of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) for the potential treatment of cancer was discussed by Bristol Myers Squibb Co. (BMS).
BioWorld Science
Conferences
New compound
Cancer